AgeX Therapeutics, Inc. (AGE)

NYSEAMERICAN: AGE · IEX Real-Time Price · USD
0.590
+0.015 (2.61%)
Dec 9, 2022 3:21 PM EST - Market closed
2.61%
Market Cap 21.63M
Revenue (ttm) 53,000
Net Income (ttm) -9.92M
Shares Out 37.95M
EPS (ttm) -0.25
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 2,858
Open 0.582
Previous Close 0.575
Day's Range 0.582 - 0.59
52-Week Range 0.516 - 1.39
Beta 1.40
Analysts n/a
Price Target n/a
Earnings Date Nov 11, 2022

About AGE

AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes and obesity; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as peripheral vascular disease ... [Read more]

Industry Biotechnology
IPO Date Nov 29, 2018
CEO Michael West
Employees 5
Stock Exchange NYSEAMERICAN
Ticker Symbol AGE
Full Company Profile

Financial Performance

In 2021, AGE's revenue was $144,000, a decrease of -60.11% compared to the previous year's $361,000. Losses were -$8.68 million, -20.16% less than in 2020.

Financial Statements

News

AgeX Therapeutics Receives Extension of Time to Attain Compliance With Stock Exchange Continued Listing Requirements

ALAMEDA, Calif.--( BUSINESS WIRE )--AgeX Therapeutics, Inc. (“AgeX”: NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, announced today that on Novemb...

2 weeks ago - Business Wire

AgeX Therapeutics Reports Third Quarter 2022 Financial Results

ALAMEDA, Calif.--( BUSINESS WIRE )--AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and ope...

4 weeks ago - Business Wire

AgeX Therapeutics Reports Second Quarter 2022 Financial Results

ALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and opera...

3 months ago - Business Wire

Dr. Joanne Hackett Appointed Chairperson of AgeX Board of Directors

ALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, announced today that Dr. Joanne ...

6 months ago - Business Wire

Early-Stage Investments for Turkish Metaverse Platform MetaAge Nears $1-Million Mark

ISTANBUL--(BUSINESS WIRE)--MetaAge, a metaverse platform based on the Solana Blockchain, has drawn almost $1 million in early-stage investments, project managers said this week. Currently, under develop...

6 months ago - Business Wire

AgeX Therapeutics Reports First Quarter 2022 Financial Results

ALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and opera...

6 months ago - Business Wire

AgeX Therapeutics Reports Fourth Quarter and Annual 2021 Financial Results

ALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and opera...

8 months ago - Business Wire

AgeX Therapeutics to Collaborate With University of California, Irvine, on Research Program for Exosome-Based Therapi...

ALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company focused on developing therapeutics for human aging and regeneration, announced today a res...

11 months ago - Business Wire

AgeX Therapeutics' Licensee ImStem Biotechnology Announces First U.S. Multiple Sclerosis Patient Dosed with IMS001

ALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company focused on developing therapeutics for human aging and regeneration, announced today that ...

1 year ago - Business Wire

AgeX Therapeutics Receives Stock Exchange Deficiency Letter

ALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics , Inc. (“AgeX”: NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, announced today that on Novembe...

1 year ago - Business Wire

AgeX Therapeutics Reports Third Quarter 2021 Financial Results

ALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and opera...

1 year ago - Business Wire

AgeX Therapeutics Reports Second Quarter 2021 Financial Results

ALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and opera...

1 year ago - Business Wire

AgeX Therapeutics and LyGenesis Terminate Merger Negotiations

ALAMEDA, Calif. & PITTSBURGH--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and cell regeneration, and LyGenesis,...

1 year ago - Business Wire

AgeX Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update

ALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and opera...

1 year ago - Business Wire

AgeX Therapeutics Reports Fourth Quarter and Annual 2020 Financial Results and Provides Business Update

ALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and opera...

1 year ago - Business Wire

AgeX Announces Preprint Article Relating to Regeneration, Aging, and Cancer

ALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, announced today the online publi...

1 year ago - Business Wire

AgeX Therapeutics to Collaborate with The Ohio State University to Generate Proof-of-Concept Animal Data for AgeX's B...

ALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, announced today a research colla...

1 year ago - Business Wire

AgeX Therapeutics and LyGenesis to Negotiate Merger Agreement

ALAMEDA, Calif. & PITTSBURGH--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and cell regeneration, and LyGenesis,...

1 year ago - Business Wire

AgeX Therapeutics, Inc. Announces That Its Annual Meeting of Stockholders Will Be Conducted Online Only

ALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE) announced today that due to state and county government health orders, attendance at the AgeX 2020 Annual Meeting o...

1 year ago - Business Wire

AgeX Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update

ALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing innovative regenerative therapeutics to treat human diseases to increase health...

2 years ago - Business Wire

AgeX Therapeutics Sublicenses Stem Cell Line ESI-053 to ImStem Biotechnology for Development of Cell Therapy Candidat...

ALAMEDA, Calif. & FARMINGTON, Conn.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (“AgeX”: NYSE American: AGE), a biotechnology company developing innovative regenerative therapeutics to treat human disease...

2 years ago - Business Wire

AgeX Therapeutics News: Why AGE Stock Is Skyrocketing 193% Today

AgeX Therapeutics (AGE) stock is soaring higher on Thursday following news of that Juvenescence has a 50% stake in the company. The post AgeX Therapeutics News: Why AGE Stock Is Skyrocketing 193% Today ...

2 years ago - InvestorPlace